IL12/23 blockade for refractory immune-mediated colitis: 2 center experience
File(s)
Author(s)
Type
Journal Article
Abstract
BACKGROUND AND AIMS: Immune checkpoint inhibitor mediated colitis (IMC) is commonly managed with steroids and biologics. We evaluated the efficacy of ustekinumab (UST) in treating IMC refractory to steroids plus infliximab and/or vedolizumab. RESULTS: Nineteen patients were treated with UST for IMC refractory to steroids plus infliximab (57.9%) and/or vedolizumab (94.7%). Most had grade ≥3 diarrhea (84.2%) and colitis with ulceration was present in 42.1%. Thirteen patients (68.4%) attained clinical remission with UST and mean fecal calprotectin levels dropped significantly after treatment (629±101.5 mcg/mg to 92.0±21.7 mcg/mg, p=0.0004). CONCLUSIONS: UST is a promising therapy for treatment of refractory IMC.
Date Issued
2023-09
Date Acceptance
2023-04-27
Citation
American Journal of Gastroenterology, 2023, 118 (9), pp.1679-1683
ISSN
0002-9270
Publisher
Lippincott, Williams & Wilkins
Start Page
1679
End Page
1683
Journal / Book Title
American Journal of Gastroenterology
Volume
118
Issue
9
Copyright Statement
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology. This is an open access article distributed under the terms of the Creative Commons AttributionNonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the
work provided it is properly cited. The work cannot be changed in any way or used commercially
without permission from the journal.
work provided it is properly cited. The work cannot be changed in any way or used commercially
without permission from the journal.
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/37216614
PII: 00000434-990000000-00766
Publication Status
Published
Coverage Spatial
United States
Date Publish Online
2023-05-22